Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Clinical trial NCT04952168 · UNKNOWN

Trial details

NCT number: NCT04952168
Sponsor: Yuan Chen
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC, Stage III

Start date: 2021-06-02
Primary completion: 2022-06-02
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.